| Dr Quinn Capers Iv, MD | |
|
2041 Georgia Ave Nw, Washington, DC 20060-1240 | |
| (202) 865-6100 | |
| Not Available |
| Full Name | Dr Quinn Capers Iv |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 33 Years |
| Location | 2041 Georgia Ave Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053312413 | NPI | - | NPPES |
| 2502581 | Medicaid | OH |
| Facility Name | Location | Facility Type |
|---|---|---|
| Parkland Health & Hospital System | Dallas, TX | Hospital |
| Ut Southwestern University Hospital - William P. Clements Jr. | Dallas, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Texas Southwestern Medical Center | 0648188250 | 2588 |
News Archive
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial results today for the third quarter and nine months ended September 30, 2011.
The non-O ABO blood type is the most important risk factor for venous thromboembolism (blood clots in veins), making up 20% of attributable risk for the condition, according to a new study in CMAJ (Canadian Medical Association Journal).
Today, Intomics A/S and LEO Pharma A/S announced a collaboration under which LEO Pharma gains access to Intomics' unique biological data analysis expertises. The recently founded spin-off company from The Danish Technical University, Intomics, has methods and tools for use in LEO Pharma's early drug discovery.
The extraordinary shareholders' meeting of convened to approve the acquisition of the US company, RedPath Integrated Pathology, will be held on first notice, on Monday, June 28, 2010 at 17:30 CET, at the Company's headquarters, 63-65 boulevard Masséna, 75013 Paris, France. If the quorum is not met, the meeting will be held, on second notice, on July 8, 2010, at 16:00 CET, at the Company's headquarters.
A new analysis indicates that certain characteristics may increase a breast cancer survivor's risk of developing leukemia after undergoing chemotherapy and/or radiation. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings are a first step toward finding ways to prevent this serious and potentially life-threatening treatment-related complication.
› Verified 1 days ago
| Entity Name | University Of Texas Southwestern Medical Center At Dallas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972579365 PECOS PAC ID: 0648188250 Enrollment ID: O20031106000792 |
News Archive
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial results today for the third quarter and nine months ended September 30, 2011.
The non-O ABO blood type is the most important risk factor for venous thromboembolism (blood clots in veins), making up 20% of attributable risk for the condition, according to a new study in CMAJ (Canadian Medical Association Journal).
Today, Intomics A/S and LEO Pharma A/S announced a collaboration under which LEO Pharma gains access to Intomics' unique biological data analysis expertises. The recently founded spin-off company from The Danish Technical University, Intomics, has methods and tools for use in LEO Pharma's early drug discovery.
The extraordinary shareholders' meeting of convened to approve the acquisition of the US company, RedPath Integrated Pathology, will be held on first notice, on Monday, June 28, 2010 at 17:30 CET, at the Company's headquarters, 63-65 boulevard Masséna, 75013 Paris, France. If the quorum is not met, the meeting will be held, on second notice, on July 8, 2010, at 16:00 CET, at the Company's headquarters.
A new analysis indicates that certain characteristics may increase a breast cancer survivor's risk of developing leukemia after undergoing chemotherapy and/or radiation. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings are a first step toward finding ways to prevent this serious and potentially life-threatening treatment-related complication.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Quinn Capers Iv, MD 2041 Georgia Ave Nw, Washington, DC 20060-7208 Ph: () - | Dr Quinn Capers Iv, MD 2041 Georgia Ave Nw, Washington, DC 20060-1240 Ph: (202) 865-6100 |
News Archive
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial results today for the third quarter and nine months ended September 30, 2011.
The non-O ABO blood type is the most important risk factor for venous thromboembolism (blood clots in veins), making up 20% of attributable risk for the condition, according to a new study in CMAJ (Canadian Medical Association Journal).
Today, Intomics A/S and LEO Pharma A/S announced a collaboration under which LEO Pharma gains access to Intomics' unique biological data analysis expertises. The recently founded spin-off company from The Danish Technical University, Intomics, has methods and tools for use in LEO Pharma's early drug discovery.
The extraordinary shareholders' meeting of convened to approve the acquisition of the US company, RedPath Integrated Pathology, will be held on first notice, on Monday, June 28, 2010 at 17:30 CET, at the Company's headquarters, 63-65 boulevard Masséna, 75013 Paris, France. If the quorum is not met, the meeting will be held, on second notice, on July 8, 2010, at 16:00 CET, at the Company's headquarters.
A new analysis indicates that certain characteristics may increase a breast cancer survivor's risk of developing leukemia after undergoing chemotherapy and/or radiation. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings are a first step toward finding ways to prevent this serious and potentially life-threatening treatment-related complication.
› Verified 1 days ago
Dr. Adefolaju Oketokun, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1629 K Street Nw, Suite 300, Washington, DC 20006 Phone: 202-636-1360 Fax: 202-636-5137 | |
Dr. Uzoamaka Theodora Nwaogwugwu, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2041 Georgia Avenue Nw, Washington, DC 20060 Phone: 202-865-7677 | |
Ms. Sruthi Nukalapati Reddy, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Road Nw, 6 Phc, Washington, DC 20007 Phone: 202-444-8123 | |
Dr. Kaustubh Subhash Yadwadkar, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Cg201, Washington, DC 20007 Phone: 304-206-7595 | |
Dr. Monica Vohra, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1525 7th St Nw, Washington, DC 20001 Phone: 202-386-7020 Fax: 202-265-1970 | |
Anteneh A Tesfaye, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw Ste C2151, Washington, DC 20010 Phone: 202-877-6998 Fax: 202-877-8909 | |
Erica Nakajima, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5255 Loughboro Rd Nw Fl 1, Washington, DC 20016 Phone: 202-660-6500 |